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Abstract
As a result of the increase of the life expectancy, elder people live with diverse diseases
or conditions like systemic disorders, immune-related disorders, and psychiatric issues.
Consecutively, practicing clinicians are faced with serving dental implant treatments in
such a population comprised of medical and demographic characteristics. Most com-
monly, implant therapy is performed among patients above middle ages; therefore,
clinicians often encounter medically compromised patients. The patients are usually
with adverse conditions like bleeding disorders, bone diseases, cardiovascular disease
(CVD), and/or immunologic conditions like cancer therapy, steroid or immunosuppres-
sive or antiresorptive medication, alcoholism, smoking, and many others. Nevertheless,
only few conditions could be stated for contraindication to dental implant therapy.
Besides the broad range of the mentioned dental implant comorbidities smoking seems
less prevalent compared to the general population. Dental implants in smoking patients
are certainly affected in relation to the failure rate, marginal bone loss, and some other
risks of postoperative complications. Hence, smoking or other similar conditions could
be accounted as a chronic systemic disorder just like diabetes mellitus or drug usage.
Briefly, it seems that establishing the medical and demographic conditions prior to
implant therapy along with controlling the systemic diseases or disorders may be more
important than the presence of compromise.
Keywords: systemic diseases, dental implant success, contraindication
1. Introduction
Dental implant (DI) is broadly considered to be the ideal treatment of the tooth loss, which is
mostly required in the aged population [1, 2]. The prevalent age-range for implant therapy has
been reported above 40 years [2] or between 51 and 60 years [1], thus the patients who required
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dental implant therapy are usually associated with systemic comorbidities. For both patients’
and clinicians’ benefit, systemic comorbidities of the patient should be well-diagnosed before
DI therapy. Besides, treatment plan and patient selection should be carried out with reference
to the clinical evidence. Patients should be ensured to inform thoroughly about the risks and
precautions.
2. Systemic disorders and compromised conditions
2.1. Elderly population
Aging has an effect on biological activity via altering the inflammatory, regenerative, and
remodeling phases of healing process. First, it makes inflammatory phase prolonged by pro-
moting the release of inflammatory mediators. Second, it decreases new tissue formation in the
regenerative phase by reducing angiogenesis and the number of mesenchymal stem cells,
which are the progenitors of new bone formation. Last, it causes an imbalance in bone
remodeling by changing cell activity, level of matrix metalloproteases, apoptosis, and collagen
turnover [3]. Therefore, it may not be wrong to consider that aging causes a delay on osseoin-
tegration of dental implants.
In the literature, there are eligible studies that have been conducted for long-term time periods
and the survival rate (SR) of dental implants is about 90% (Table 1). Furthermore, in a recent
meta-analysis, SR has been reported to be 91.2% for up to 10 years [4]. On the other hand,
considering the peri-implant pathology and bone level changes, studies have unsatisfactory
results. According to the aforementioned meta-analysis [4], there is only one prospective
clinical study that reports peri-implant marginal bone loss (MBL) after 10 years as 1.5 mm [5].
Additionally, another reviewer states that peri-implant mucositis and peri-implantitis are
observed more commonly in totally edentulous patients, which are mainly ≥65 years old [3].
2.2. Tobacco smoking
Tobacco consumption is one of the main considerable patient-related systemic conditions for
the patients who require DI. Though smoking is not a contraindication for DI therapy, there
have been a lot of studies that report negative effects on DI outcomes.
According to the clinical studies (Table 2), there is a tendency to consider that implant failure is
correlated with smoking habits. Most of the studies confirm the association between smoking
and increased failure rate of implants in both short- and long-term periods. Besides, tobacco
smoking has been proved to increase the failure rate of DI from 2.5- to 3-fold [9, 12]. However,
there is only one study that has showed a higher survival rate of DI in smoker patients [13].
People who consume 10–20 cigarettes daily are often counted as heavy smokers in clinical
studies. And despite a small number of studies that reveal the effect of the number of cigarettes
on failure, it has been demonstrated that consuming the 6–15 cig/day doubled the risk of
implant failure [9].
Clinical Trials in Vulnerable Populations60
Author, year, study
design
Follow-
up
No. of patients No. of
implants
SR of implant Peri-implant
pathology
Conclusion
Moy et al.,
2005, Retrospective
cohort [6]
2–20
years
541 subjects are
aged >60 years
(1140 total)
ND
(4680
total)
82% (for aged
>60 years)
– Patients who are aged
>60 years have higher
risk for implant failure
(RR = 2.24)
Manor et al., 2009,
Retrospective
cohort [7]
6 years 194 (2 equal
groups for
evaluating
early and late
failures)
294 – Assigned as minor/
moderate/major
MBL
Old age may be a risk
factor for late failures
and risk is also more
likely for men and
posterior of jaws
Lee et al., 2010,
Prospective [8]
2.7
years
(mean)
35 subjects are
>70 aged
geriatric MCP
with controlled
systemic
disease
118 – MBL: 0.27 mm Old age is not a risk
factor for peri-implant
MBL (p = 0.484)
Busenlechner et al.,
2014, Retrospective
[9]
8 years 2632 subjects
are >50 years
(61% out of
4316 total)
ND 95.3% for the
age >70 years
– Old age over 70 years
is not associated with
long-term implant
success
Becker et al., 2015,
Prospective [10]
7 years 31 aged
subjects
84 94.6% for 13
patients with
40 implants
MBL: 0.1 mm
(difference of 0–7
years’ follow-up)
PD: 2.6 mm
DI is successful in
aged population, and
MBL changes are
comparable with the
younger populations
Neves et al., 2016,
Retrospective [2]
7.3
years
(mean)
528 subjects are
aged >40 years
(721 total MCP
subjects with
the age range of
20–87)
ND
(3998
total)
92.7% for the
age <40, 85.3%
for age >40,
and 86.5% is
overall SR
(patient
based)
33.8% of patients
and 12.7% of
implants have
pathology
>40 age is a risk factor
of implant loss (risk is
higher for more than
two times than <40
age), but is not a risk
for peri-implant
pathology
Prasad et al., 2016,
Retrospective
cohort [11]
5.7
years of
mean
Approximately
the half of 1091
total subjects is
aged >60 years
ND
(1918
total)
96.4%
(implant
based), 94.6%
(patient
based)
– Age over 65 years is
shown to have an
increased risk of
implant failure
Hoeksema et al.,
2016, Prospective
comparative [5]
10
years
(1) 52 subjects
with age range
of 35–50 years
(2) 53 subjects
with age range
of 60–80 years
(1) 104
(2) 106
(1) 97.1%
(2) 93.4%
MBL: 0.1 mm (1st
year), 0.7 mm (5th
year), 1.5 mm (10th
year)
PD: 3 mm for both
groups at 10th year
Mandibular two-
implant OD is equally
successful in older
patients compared
with the younger
patients without
significant differences
of the parameters
Srinivasan et al.,
2016, Sys. Rev.,
meta-analysis [4]
(includes 11
prospective
studies)
1–10
years
206 subjects are
aged ≥65 years
480 97.7% (1st
year), 96.2%
(5th year),
91.2% (10th
year)
MBL: 0.1–0.3 mm
(1st year), 0.7 mm
(5th year), 1.5 mm
(10th year)
Age alone should not
be a limiting factor for
DI therapy Reported
complications are
found inadequate for
a meta-analysis
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Regarding the MBL, smoking seems to have a destroying effect by increasing the annual rate of
MBL by 0.164 mm/year [14], and MBL is about 1.4 mm after 3 years with a statistically
significant difference from people who do not smoke tobacco [15, 16].
As a result, tobacco smoking alone is not contraindicated for DI, and DI survival is about 90%
for a long time period. On the other hand, smokers are under a higher risk of implant failure
compared to the nonsmokers. Thus, clinicians should take into account other concomitant
systemic factors which could increase the risk of failures.
2.3. Alcohol consumption
There is no evidence to suggest that alcoholism is a contraindication for DIs. SR of DI is similar
to healthy population with a reasonable alcohol consumption. Nevertheless, alcoholism is
claimed to increase the risk of complications for DI because it may cause many systemic
disorders like liver disease, bleeding disorders and osteoporosis (OP), and it may impair
immune response and some nutritional elements like folate and B vitamins, and it is often
associated with tobacco smoking [28].
It is reported that consumption of >10 g of alcohol increases the MBL and decreases DI survival
in humans [15]. Despite there are few studies available (Table 3) concerning the DI outcomes
in patients who consumed high level of alcohol, further clinical studies with well-defined
subjects are required for clarifying the relation.
2.4. Cardiovascular diseases
Cardiovascular disease (CVD) compromises the blood flow which may restrict oxygen or
nutrients in the osseous tissue, thus is hypothesized to have higher risk of osseointegration
failure [29–31]. Clinical studies and reviews demonstrate no evidence of contraindication
related to DI success in patients with CVD (Table 4), and this disease is registered as a relative
complication due to the risk of infective endocarditis. Antibiotic prophylaxis is necessary prior
to the surgery [31] according to the guidelines of the American Heart Association’s last
publish [32, 33].
Author, year, study
design
Follow-
up
No. of patients No. of
implants
SR of implant Peri-implant
pathology
Conclusion
Mean/total of
values/subjects and
considerations
1–20
years
4765 patients
above middle
ages
>1082 SR is 90% for
long-term
period
0.1 mm in the 1st,
1.7 mm in the 5th,
and 1.5 mm in the
10th year follow-
ups (out of 3 in
available 8 studies)
Implant therapy is a
successful treatment
in the medically
compromised patient
MCP, medically compromised patients; DI, dental implant; SR, survival rate; MBL, marginal bone loss; BoP, bleeding on
probing; RR, risk ratio; ND, no data available; OD, overdenture.
Table 1. Studies that indicate dental implant outcomes in the elderly population.
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Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant
pathology
Conclusion
Ekfeldt et al., 2001,
Retrospective controlled
study [17] (half of subjects lost
at least half of their implants)
8 years 54 total (half part is smoker,
and 9 of them defined as
heavy smokers who
consumed ≥10 cig/day)
ND 31 DI loss in 7
heavy smokers
(at least half of
their implants)
6% of implants
had infection
during healing in
smokers
Except from instability associated
with bad bone quality, implant
losses mostly occur in patients with
heavy smoking habits or bruxism.
It is more prominent in post-
loading period (22 implants had
lost after loading in 7 patients of
heavy smokers)
Moy et al., 2005,
Retrospective [6]
2–20 years 173 smoker ND 79.77% for
smokers
– There is a correlation between
smoking and increased failure rate
(RR = 1.56)
Galindo-Moreno et al., 2005,
Prospective [15]
3 years 63 smoker ND (514 total) – MBL is 1.36 mm
in smokers
MBL is significantly related to
tobacco smoking
Alsaadi et al., 2007,
Retrospective [18]
Up to the
abutment
connection
ND (2004 total) 6946 total (343
heavy smoker
who consumed
>20 cig/day)
92.95% for heavy
smokers
– Smoking of >20 cig/day is shown
significantly higher early implant
failure when compared to no
smoking groups
Holahan et al., 2008,
Retrospective chart review [19]
5 years 24 smoker 83 in smokers 88% for smokers – Implants placed in smokers are 2.6
times more likely to fail than
implants placed in nonsmokers
Sverzut et al., 2008,
Retrospective [20]
<1 year 76 smoker (out of 650 total) 197 in smokers
(1628 total)
97.19% for
smokers, 96.68%
for nonsmokers
– Tobacco use alone cannot be
considered as a factor for risk
related to early implant failures
Alsaadi et al., 2008,
Retrospective [21]
2 years 22 (>20 cig/day) 93 implants in
patients who
consumed >20
cig/day
93.94% – Smoking does not seem
predominant player for late
implant loss
Alsaadi et al., 2008,
Prospective [22]
<1 year 90 smoker 95 in smokers 94.44% – Tendency for more early implant
failures is noticed in smokers
Lee et al., 2011,
Retrospective [23]
5 years ND (95 total) ND (249 total) ND ND Implant failures are correlated with
smoking
Cakarer et al., 2014,
Retrospective [24]
5 years ND 246 in smokers – Smoking is not affected the DI
survival
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Author, year, study design Follow-up No. of patients No. of implants SR of implant Peri-implant
pathology
Conclusion
97.5% (6 failed
out of 246
implant)
Busenlechner et al., 2014,
Retrospective [9]
8 years 1726 smoker ND (13147 total) 76.5% for
smokers (overall
SR is 97%)
– Smoking increases the failure rate
by 3-fold 6–15 cig/day doubles the
risk of implant failure
Tran et al., 2016, Retrospective
chart review [12]
10 years 215 smoker (2729 total) – – Smoking increases the failure rate
by 2.6-fold
Krennmair et al., 2016,
Prospective cohort [16]
3 years 9 smoker (out of 44 total) ND – 1.45* mm in
smokers
Smoking is risk factors for MBL
(OR: 8.9)
Neves et al., 2016,
Retrospective [2]
7.3 years
of mean
476 smoker ND 85.1% (patient
based)
36.6% pathology
rate (patient
based)
Smoking is not associated with
higher risk of implant failure and
peri-implant pathology (>4 mm
pocket depth with BoP or MBL)
Pedro et al., 2017, Analytical,
observational, longitudinal
study [25]
2–4 years ND (18 total) ND (57 total) – ND Smoking has an influence on both
mesial and distal bone loss (p =
0.037)
Niedermaier et al., 2017,
Retrospective cohort [13]
7 years 141 smoker (out of 380 total) ND (2081 total) 98.6% for
smokers, 96.1%
for nonsmokers
– Smokers have a significantly higher
DI survival rate than nonsmokers
Clementini et al., 2014,
Systematic review and meta-
analysis [14]
>1 year 478 smoker and 1207
nonsmoker
ND ND Smoking
increases the
annual rate of
MBL by 0.164
mm/year
Smoking has a harmful effect on
peri-implant bone loss. However,
the level of evidence for oral
implant therapy in patients with
systemic conditions is very low
Mean/total of values/subjects 1–20 years 3520 patients with smoking
habits (13 out of 17 available
studies)
1057 implants in
smokers (6 out
of 17 available
studies)
SR is about 90%
for smokers
Apprx. 1.4 mm
MBL after 3 years
Smoking has a negative impact on
the success and survival of dental
implants
Statistically significant difference with healthy groups.DI, dental implant; SR, survival rate; MBL, marginal bone loss; BoP, bleeding on probing; OR, odds ratio; RR, risk
ratio; ND, no data available.
Table 2. Studies that indicate dental implant outcomes in patients with smoking habits.
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DI surgery is suggested as a legitimate procedure for the patients at high risk for IE (such as
aortic or mitral valve replacement or cyanotic congenital malformation) which under prophy-
lactic antibiotic regime of 2 g amoxicillin orally at 1 hour preoperatively [34]. There is also
evidence suggesting that this regimen significantly reduces failures of DIs though it is still
unknown whether postoperative antibiotics are more beneficial, and which antibiotic is the
most effective [33]. Reviewers stated the importance of concomitant bleeding or cardiac ische-
mia which could develop during DI insertion, therefore, procuring medical advice is
recommended prior to the implant surgery [28]. As a matter of fact, recent myocardial infarc-
tion, stroke, and cardiovascular surgery are well-known contraindications for performing DI
surgery [35].
According to the current literature, CVD does not hinder the osseointegration of DI [36, 37]
and is not associated with higher risk of implant failure (Table 4). SR is about 89% up to 20
years (Table 4). However, the number of the studies that reports peri-implant health condition
is insufficient. Unlike the other studies available, one study revealed that CVD has risk factors
for peri-implant bone loss with the mean value of 1.38 mm after 3 years [16]. Further studies
are needed in this respect.
2.5. Diabetes
As being the most prevalent endocrine disease, diabetes mellitus is a metabolic disorder that is
generally diagnosed by the characteristic symptoms of polydipsia, polyuria, and polyphagia in
correlation with exceeded blood glucose levels more than 200 mg/dL. It causes hyperglycemia
due to a defect of insulin secretion [39], that insulin has an effect on the regeneration of bone
matrix. In a diabetic patient, hyperglycemia reduces clot quality, number of osteoclasts, and
collagen production, which are the keys of bone regeneration [30].
Author, year,
study design
Follow-
up
No. of patients No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Galindo-Moreno
et al., 2005,
Prospective [15]
3 years 23 alcohol users ND – MBL: 1.66
mm
MBL is significantly related to
a daily consumption of >10 g
of alcohol
Gander et al.,
2014,
Retrospective [26]
20
months
33 (29 patients with
SCC, 24 underwent
mandibular
reconstruction)
136 total 92.7% (at 1st
year), 87.5%
(after 20th
month)
– In head and neck oncology
patients alcohol (p = 0.001) is
associated with higher
implant failure rate
Scully et al., 2007,
Review [27]
ND ND ND Similar to
healthy
population
– May not be a risk for DI
Diz et al., 2013,
Review [28]
ND ND ND Similar to
healthy
population
– May be at increased risk of
complications for DI
MBL, marginal bone loss; ND, no data available; SR, survival rate; SCC, squamous cell carcinoma; DI, dental implant.
Table 3. Studies that indicate dental implant outcomes in patients with alcohol abuse.
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Author, year, study
design
Follow-up No. of patients No. of
implants
SR of implant Peri-implant
pathology
Conclusion
Moy et al., 2005,
Retrospective cohort [6]
2–20 years 1140 total (202 with
hypertension, 106
with CVD, 75 with
pulmonary disease)
ND (4680 total) 85% for
hypertension,
85% for CVD
– There is no correlation between hypertension,
coronary artery disease, pulmonary disease and
increased failure rate of DI
Alsaadi et al., 2007,
Retrospective [18]
Up to the
abutment
connection
ND (2004 total) ND (6946 total) ND – Cardiac disease is not associated with increased
incidence of the early failures
Alsaadi et al., 2008,
Retrospective [21]
2 years 19 subjects with CVD 76 in subjects
with CVD
90.79% – Cardiac problem does not seem a predominant
player for late implant loss
Neves et al., 2016,
Retrospective [2]
7.3 years
of mean
222 subjects with
CVD
ND 89.2% (patient
based)
32% (patient based) Cardiac disease is not associated with higher risk
of implant failure and peri-implant pathology
(>4 mm pocket depth with BoP or MBL)
Nobre et al., 2016,
Retrospective [38]
5 years
after
loading
70 total (CVD
subjects: 38 patients;
non-CVD subjects: 32
patients)
352 CVD: 86.7%;
non-CVD:
93.8%
MBL at 1st and 5th
year is 0.95–1.52 mm in
CVD; 0.78–1.54 mm in
non-CVD group
Implant rehabilitations represent a valid
treatment for diabetic patients with or without
coexisting CVD, with a good risk/benefit ratio
(nonsignificant differences between the groups)
Krennmair et al., 2016,
Prospective cohort [16]
3 years 19 subjects with CVD
(out of 44 total)
ND – 1.38 mm in CVD* CVD is risk factors for bone loss. (OR: 5.1)
Pedro et al., 2017,
Analytical,
observational,
longitudinal [25]
2–4 years ND (18 total) ND (57 total) – ND Heart diseases are not a contraindication for DI
bone loss
Niedermaier et al.,
2017, Retrospective
cohort [13]
7 years 95 subjects with CVD
(380 total)
ND (2081 total) 97.8% – DI survival in patients with cardiovascular
problems does not differ from the healthy
control subjects
Mean/total of values/
subjects
2–20 years 1533 patients with
CVD (in 6 out of 8
available studies)
428 (in 2 out of
8 available
studies)
Approx. 89%
SR
0.95 mm at 1st year
1.38 mm at 3rd year
1.52 mm at 5th year
CVD may not pose a risk for dental implants
Statistically significant difference with healthy groups.CVD, cardiovascular disease; RD, rheumatic disorders; OR, odds ratio; MBL, marginal bone loss; ND, no data
available; SR, survival rate.
Table 4. Studies that indicate dental implant outcomes in patients with cardiovascular diseases.
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A decreased bone density is observed around the titanium implants in animal subjects, and
implant survival is slightly reduced in poor metabolic control [28] with an average rate of 89%
(Table 5). Yet no clinical evidence exists to establish an association of glycemic control with
implant failure because of the insufficient identification and reporting of glycemic control in
most of the published studies [40].
Though diabetes is not a contraindication for DI therapy, evaluating the HbA1c level of the
patient and chlorhexidine mouth wash and antibiotic prophylaxis are recommended in order
to reduce the relative risk of infection associated with diabetes [28, 30].
2.6. Bleeding disorders
There is no evidence to suggest that bleeding disorders (BDs) are contraindication for place-
ment of DIs [28] or a contraindication for implant survival/success [31]. Since the risk of
thromboembolism of interrupting or changing the antiplatelet therapy is higher than the risk
of hemorrhage caused by dental implant surgery, invasive dental procedures including dental
implant surgery are suggested to perform normally [42].
Considering the oral anticoagulant therapy (OAT), DI is not contraindicated in patients
under an OAT [28, 31]. Minor DI surgery (that does not involve autogenous bone grafts,
extensive flaps, or osteotomy preparations extending outside the bony envelope) is asserted
to be safe regarding the risk of hemorrhage in patients who have an INR value of 2–4, and
local hemostatic agents are suggested enough for these patients [43, 44]. On the other hand, it
should be noted that some medications that are commonly used in dental practice (like
metronidazole, erythromycin, and clarithromycin) may increase the anticoagulant effect of
warfarin [31].
There are some additional precautions for the patients with inherited BDs such as taking
medical advice previously, the replacement of deficient coagulation factor to reach a minimum
level of 50% before surgery, slow injection of local anesthesia with vasoconstrictor, the use of
antifibrinolytic agents (oral tranexamic acid and/or 5% tranexamic mouthwash) up to 7 days
postsurgically, and the use of topical antiseptics (chlorhexidine or povidone iodine) in order to
reduce the risk of local infection. Sinus lifting and bone graft procedures are recommended to
be avoided, and consulting for the use of nonsteroidal anti-inflammatory drugs is advised as
they may increase the risk of a dangerous hemorrhage [31].
Studies that analyze the bleeding risk and DI success after invasive DI surgeries are lacking
(Tables 6 and 7). Studies are also required for evaluating whether anticoagulants have an effect
on DI therapy negatively or which is the optimum drug or regimen.
2.7. Thyroid disorders
Thyroid hormones of triiodothyronine (T3) and thyroxine (T4) have been demonstrated to
have influence on cortical bone healing than cancellous bone around titanium implants [47].
Thus, thyroid hormones-related disorders could be regarded as the considerable issues for
evaluating the success of dental implants.
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Author, year,
study design
Follow-up No. of
patients
No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Moy et al., 2005,
Retrospective
cohort [6]
2–20 years 48 diabetic ND 68.75% in
diabetic
patients
– There is a correlation between
diabetes and increased failure
rate (RR = 2.75)
Alsaadi et al.,
2007,
Retrospective [18]
Up to the
abutment
connection
ND ND ND – Controlled diabetes type 2 is not
associated with increased
incidence of the early failures
Alsaadi et al.,
2008,
Retrospective [21]
2 years 9 33 100% – Diabetes type 2 does not seem
predominant player for late
implant loss
Busenlechner
et al., 2014,
Retrospective [9]
8 years 185 (4.3% out
of 4316 total)
ND 95.1% for
diabetes
(overall
97%)
– Diabetes is not associated with
long-term implant survival (p =
0.928)
Neves et al., 2016,
Retrospective [2]
7.3 years
(mean)
56 diabetic ND 92.9%
(patient
based SR)
26.8%
patient
based
Diabetes is not associated with
higher risk of implant failure and
peri-implant pathology (>4 mm
PD with BoP/MBL)
Niedermaier
et al., 2017,
Retrospective
cohort [13]
7 years 9 ND 91.9% – DI survival in diabetic patients
does not differ from the healthy
control subjects
Shi et al., 2016
Meta-analysis
[41] (abstract
available)
ND 252 587 ND – There is no difference between
the failure rates of the patients
with uncontrolled and well-
controlled diabetes
Diz et al., 2013,
Review [28]
ND ND ND Slightly
reduced in
bad
metabolic
control
– Evaluating the HbA1c level for
patient selection, avoiding
hypoglycemia, using
chlorhexidine and antibiotic
prophylaxis are recommended
for diabetic patients
Oates et al., 2013,
Review [40]
Unrestricted – – Implant
failure rates
ranging
from 0 to
9.1%
– Clinical evidence is lacking for
the association of glycemic
control with implant failure,
because the identification and
reporting of glycemic control are
insufficient or lacking in most of
the published studies
Mean/total of
values/subjects
2–20 years 559 diabetic
patients (in 6
out of 7
available
studies)
620 (in 2
out of 7)
Approx.
89% SR
Diabetes may interfere with the
SC and SR pf implants
DI, dental implant; BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; SR, survival rate; RR, risk
ratio; PD, pocket depth.
Table 5. Studies that indicate dental implant outcomes in patients with diabetes.
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Concerning the peri-implant pathology, thyroid disorders are reported to have the lowest
potential risk compared to the other systemic disorders, in a recent clinical study [2] (Table 8).
Due to the limited number of clinical studies that report DI outcomes in patients with thyroid
disorders, it is hard to deduce a suggestion. Therefore, there is a certain need for further
studies about the thyroid disorders.
2.8. Hepatitis
Concerning the dental implantology, hepatitis is one other disease which has not been studied
widely yet. These infectious diseases impair immune system, increase oxidative stresses
induced by the viral proteins, and cause virus-associated organ damage including liver fibro-
sis, steatosis, or hepatocellular carcinoma [48].
Author, year,
study design
Objective of the study No of
patients
Conclusion related to surgical risks of DI
Clemm, 2016,
Clinical
comparative
study [45]
Postoperative bleeding risk of patients
continuing their anticoagulation therapy
(antiaggregant, vit-K inhibitors, vitamin-
K inhibitor withdrawal bridged with
heparin, direct oral anticoagulants) and
undergoing implant surgery and
advanced bone grafting procedures
564
patients
1. No thromboembolic complication occurred
2. The postoperative bleeding risk after
implant surgery and/or bone grafting pro-
cedures is very low in patients continuing
the anticoagulant therapy
3. The invasiveness of the surgical procedure
had no statistically significant effect on
bleeding frequencies
4. Patients taking vit-K inhibitors had a sig-
nificantly higher risk of a postoperative
bleeding compared to patients without any
anticoagulant
5. Most of the postoperative bleedings are
easily controllable via local hemostatic
measures
Table 6. Hemorrhagic risks in patients undergoing advanced implant surgery and bone grafting procedures.
Author, year, study
design
Follow-up No. of
patients
No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Markovic et al., 2016,
Randomized
study [46]
1 year 20 80 100% for
both
groups
– There is no difference between
healing of the hydrophilic and
hydrophobic TiZr implant surface.
OAT influences the bone healing
by resulting in lower ISQ at 3rd
month in comparison with baseline
values, although without
compromising implant stability
OAT, oral anticoagulation therapy; ISQ, implant stability quotient; SR, survival rate.
Table 7. Studies that indicate dental implant outcome in patients with bleeding disorders or under an anticoagulant
therapy.
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Being one of the most spread and dangerous human pathogens, hepatitis C is shown to affect
the oral conditions by increasing decays, gingival bleeding, and pocket depth due to the
evident change in salivary flow [49].
Though hepatitis was indicated only as a possible risk factor previously [50], a present report is
registered that hepatitis is the only risk factor for peri-implant pathology among the other
systemic compromising factors such as cardiac diseases, thyroid disorders, diabetes, rheuma-
tologic disorders, HIV infection, and smoking [2] (Table 9).
2.9. Bone diseases
Being the most frequent bone disorder, osteoporosis (OP) affects both bone mass and density.
The effect is also more prominent in cancellous bone and in women [30].
Clinical studies have demonstrated that a SR of DIs in the patients with the diagnosis of OP is
about 94% (Table 10). Despite a small number of studies that report peri-implant conditions,
one study has presented a high rate of peri-implantitis in patients with OP (76.1%), but this
rate does not differ from the healthy population or the patients with osteopenia [51]. Regard-
ing the peri-implant MBL, one recent study has reported a mean value of 0.11 mm at first
Author, year,
study design
Follow-up No. of
patients
No. of
implants
SR of implant Peri-
implant
pathology
Conclusion
Alsaadi et al., 2008,
Retrospective [21]
2 years 25 Hypo-
6 Hyper-
111 Hypo-
22 Hyper-
93.69% Hypo-
86.36% Hyper-
– Hypo- or hyperthyroidism
does not seem a predominant
player for late implant loss
Neves et al., 2016,
Retrospective [2]
7.3 years
of mean
37 ND 86.5% (patient
based SR)
18.9%
(patient
based)
Thyroid disorders are
associated with neither higher
risk of implant failure nor peri-
implant pathology (>4 mm PD
with BoP or MBL)
Mean/total of
values/subjects
Up to 7
years
68 133 (in
one study
available)
Further studies are required
BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; SR, survival rate; PD, pocket depth.
Table 8. Studies that indicate dental implant outcomes in patients with thyroid disorders.
Author, year,
study design
Follow-
up
No. of
patients
No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Neves et al., 2016,
Retrospective [2]
7.3 years
of mean
12 with
hepatitis
ND 83.3%
(patient
based)
66.7%
(patient
based)
Hepatitis is not associated with higher risk of
implant failure but it is a risk factor for peri-
implant pathology (OR = 3.74) (>4 mm PD
with BoP or MBL)
OR, odds ratio; BoP, bleeding on probing; MBL, marginal bone loss; ND, no data available; PD, pocket depth.
Table 9. Studies that indicate dental implant outcomes in patients with hepatitis.
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Author, year,
study design
Follow-up No. of patients No. of
implants
SR of
implant
Peri-implant
pathology
Conclusion
Alsaadi et al.,
2007,
Retrospective [18]
Up to the
abutment
connection
ND ND ND – OP is found significantly
associated with early
implant failures (OR:
2.88)
Alsaadi et al.,
2008,
Retrospective [21]
2 years 19 subjects with
OP
68 86.76% – OP does not seem
predominant player for
late implant loss
Holahan et al.,
2008,
Retrospective
chart review [19]
5 years 41 with OP
(21.4% of 192
total), 57 with
OPN (29.7% of
total)
ND ND – OP or OPN is not a
contraindication to DI.
No association between
BMD T-score and DI
survival is found
Busenlechner
et al., 2014,
Retrospective [9]
8 years 151 subjects with
OP (3.5% out of
4316 total)
ND 94.4% for
OP-
subjects
(overall
rate is
97%)
– OP is not associated with
long-term implant
survival (p = 0.661)
Dvorak et al.,
2011, Cross-
sectional
study [51]
6 years 47 subjects with
OP, 16 with OPN,
140 are healthy
controls
ND 81% for
OPN,
87% for
OP, 87%
for the
control
Peri-implantitis
rates: 75% in the
OPN, 76.1% in
OP group, 76.5%
in the control
There is no relation
between (neither OPN
nor OP) bone status and
peri-implantitis or
implant loss
Siebert et al.,
2015,
Comparative
prospective [54]
1 year 24 women (the
half was under iv.
5 mg zoledronic
acid once-yearly,
others without
OP)
120 100% ND The mean MBL is similar
for both groups.
Immediate implant
osseointegration can be
successful in patients
who received iv.
zoledronic acid
Chow et al., 2016,
Prospective [53]
5 year 79 subjects with
OP
158 98.7% MBL 0.65 mm
BOP 49.6%
PI 47.4%
OP is not a
contraindication for DI,
and reduced skeletal
BMD is not associated
with increased MBL.
BOP is found
significantly correlated
with MBL
Niedermaier
et al., 2017,
Retrospective [13]
7 years 7 subjects ND 94.1% – OP under the medication
with BF seems to be a
risk factor for success of
DI
Temmerman
et al., 2017,
Prospective
nonrandomized
controlled
multicenter [52]
1 year 20 subjects with
OP, 28 control
subjects
63 in OP-
patients,
85 in
control
98.4% is
for OP
group,
100.0% is
for
control
group
MBL: 0.11  0.49
mm for OP
group; 0.05 0.52
mm for control
group (implant
based)
DI in patients suffering
from OP/OPN is a
reliable treatment
compared to healthy
patients. Long-term
follow-up is necessary
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year [52], and one other has reported a mean of 0.65 mm at fifth year [53]. Additionally, bone
status does not seem to be a predisposition for DI failures.
2.10. Rheumatologic disorders
Rheumatologic disorders encompass a large number of diseases and syndromes such as
rheumatoid arthritis, osteoarthritis, and osteoporosis, which are the most common rheumato-
logic diseases (RDs) [2]. Different RDs could affect DI success in different ways [28]. For
instance, rheumatoid arthritis (RA) has not stated a predominant player for late implant loss
in one study [21]. However, together with the connective tissue disease, RA increases bone
resorption when compared to the connective tissue disease alone [55].
Today, there are only a few number of clinical studies with limited amount of participants that
evaluate the success of DIs in patients with RD. Although RDwas shown as risk factor for peri-
implant MBL in a recent prospective study [16], no relationship was found with the implant
failure risk or peri-implant pathology in another study [2]. Therefore it can be concluded that
any relation of RD in DI success is unclear, and there is a certain need for further studies with
sufficient number of participants (Table 11).
2.11. Bisphosphonate therapy
Bisphosphonates (BFs) suppress the osteoclast function and therefore are used for the treat-
ment of disorders causing abnormal bone resorption such as OP, malignancies (multiple
myeloma, bone metastases of breast, or prostate cancer), or nonmalignant bone diseases (the
most prevalent of osteoporosis and Paget disease) [30, 37].
According to the recent meta-analyses, the consumption of oral BF in patients with OP
could only be assumed to be a relative contraindication for DI. Further, there is no evi-
dence that any BFs have a negative impact upon implant survival. In this context, patients
should be informed about the related risks and DI could be placed under optimum oral
care conditions. On the contrary, in patients who are under BF treatment intravenously
together with RT doses of above 50 Gy, DI placement was reported to be a contraindica-
tion [30, 56].
Author, year,
study design
Follow-up No. of patients No. of
implants
SR of
implant
Peri-implant
pathology
Conclusion
Mean/total of
values/subjects
1–8 years 388 (in 8 out of 9
available studies)
409 (in 4
out of 9
available
studies)
94% SR
in
patients
with OP
Mean MBLs are
0.11 mm at 1st
year and 0.65 mm
at 5th year
follow-ups
Bone disease does not
seem to be associated
with the peri-implantitis
or failure of DIs
OP, osteoporosis; OPN, osteopenia; OR, odds ratio; ND, no data available; BMD, bone mineral density; MBL, marginal
bone loss; DI, dental implant; SR, survival rate.
Table 10. Studies that indicate dental implant outcomes in patients with bone diseases.
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In conclusion, BFs do not seem to have an adverse effect on DI survival under optimum oral care
conditions, andOBFs are not associatedwith occurrence of osteonecrosis of jaws (ONJ) (Table 12).
2.12. Head and neck cancer
Squamous cell carcinoma, adenocarcinoma, and ameloblastoma are the most common malignan-
cies that are encountered in the head and neck regions. These patients with malignancies fre-
quently go under challenging adjuvant therapeutic procedures such as radiotherapy (RT) or
chemotherapy (CT) in addition to the tumor surgery. Due to the aggressive nature of the cancer
and challenging cancer therapies, it is difficult to manage the DI surgery and prosthetic procedures.
Furthermore, studies that evaluate the DI success in cancer patients are limited because most
of the studies had a control group of patients who are under another cancer treatment (instead
of a healthy control group) or have no control subjects to compare the success of dental
implants. Therefore, the results are sufficient to achieve a conclusion regarding DI success
(Tables 13 and 14). According to these clinical studies, CT does not seem to be associated with
the higher DI failure when compared with the surgical treatment only. RT seems to be
impairing the osseointegration process. Regardless of the cancer-treatment procedure,
smoking and alcohol consumption in patients diagnosed with head and neck cancer yield
higher implant failures. Additionally, there are no studies about implant therapy in patients
with malignant diseases that are treated with BFs [64], and no study determined peri-implant
conditions of DI in such patient population.
For improving the DI success in cancer patients, implant surgery is recommended to be
performed at least 21 days prior to the initiation or following after 9 months of radiotherapy
under a strict surgical asepsis and antimicrobial prophylaxis. Premature loading of the
implants should be avoided [28, 31].
Author, year,
study design
Follow-
up
No. of
patients
No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Alsaadi et al., 2008,
Retrospective [21]
2 years 6 patients
with RD
28 100% – RA does not seem predominant player for
late implant loss
Krennmair et al.,
2016,
Prospective [16]
3 years 6 patients
with RD
(44 total)
ND – 1.61 mm
in RD
RD is risk factors for bone loss (OR: 50.1)
Neves et al., 2016,
Retrospective [2]
7.3
years
(mean)
36
patients
with RD
– 80.6%
(patient
based)
25%
(patient
based)
RDs are associated neither with higher risk
of implant failure nor peri-implant
pathology (>4 mm pocket depth with BoP
or MBL). However, it is associated with a
higher number of implant failures
RD, rheumatologic disease; RA, rheumatoid arthritis; BoP, bleeding on probing; MBL, marginal bone loss; DI, dental
implant; SR, survival rate; ND, no data available; OR, odds ratio.
Table 11. Studies that indicate dental implant outcomes in patients with rheumatologic disorders.
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Author, year,
study design
Follow-
up
No. of
patients
No. of
implants
SR of implant Peri-implant
pathology
Conclusion
Jeffcoat, 2006,
Longitudinal
single-blind
controlled [57]
3 years 50 (the half is
under OBF,
the other half
is not used
BF)
210 100% for OBF,
and 99.2% for
control group
– OBF usage is not associated
with occurrence of ONJ
compared to placebo
Martin et al.,
2010, Cohort [58]
>1 year 589 aged
women
ND 26 implants loss
in 16 patients
– Implant failure occurred as
early as 4 weeks and as late
as 11 years after placement
Famili et al., 2011,
Retrospective [59]
1 year 211 women 347 98.7% – OBF therapy is not
significantly affects implant
success
Al-Sabbagh et al.,
2015,
Retrospective [60]
6 years 39 51 86.4% – It is suggested that there is a
possible association between
implant failure and not using
of BF in elder patients (OR:
9.22)
Mozzati et al.,
2015, Clinical
chart review [61]
10
years
235 middle-
aged women
under OBPs
for OP
1267 98.7% (implant
based) 93.2%
(patient based)
– The risk for developing
BRONJ associated to DI
surgery remains low for
patients receiving oral BPs.
The use of procedures that
could enhance healing such
as platelet concentrates is
recommended
Siebert et al.,
2015,
Comparative
prospective [54]
1 year 24 women
(half under
iv. BF, others
without OP)
120 100% ND (MBL is
similar)
Immediate implant
osseointegration can be
successful in a patient with
OP using once-yearly
infusion of 5 mg iv.
zoledronic acid
Suvarna et al.,
2016,
Retrospective [62]
3 years 112 (58
patients on
OBF therapy)
140 92% – No significant risk of implant
failure is seen in patients on
OBP therapy compared with
healthy patients
Tallarico et al.,
2016,
Prospective [63]
3 years 32 98 98% 1.35  0.21 No prosthesis failed during
the entire follow-up, and no
major complications were
recorded. OBF therapy is not
significantly affecting DI
success in case of accurate
treatment selection,
minimally invasive surgical
approach and constant
follow-up
Ata-Ali et al.,
2016, Systematic
review and meta-
analysis [56]
1–7
years
1288 patients
(386 cases
and 902
controls)
4562
(1090 DI
in cases,
Ranged between
66.7 and 100% in
BF users, 95.5
– There is not enough evidence
that BFs have a negative
impact upon implant SR
Further, prospective studies
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Author, year,
study design
Follow-
up
No. of
patients
No. of
implants
SR of implant Peri-implant
pathology
Conclusion
3472 in
controls)
and 100% in
nonusers
involving larger sample sizes
and longer durations of
follow-up are required to
confirm these results
Mean/total of
values/subjects
1–10
years
1238 2233 (in 7
out of 8
available
studies)
SR is about 97%
in patients who
are under BFs
therapy
1.35 mm at
3rd year
follow-up (in
one study
available)
BFs do not seem to have an
adverse effect on DI survival
under an optimum oral care
conditions, and OBFs are not
associated with occurrence of
ONJ
BF, bisphosphonate; OBF, oral bisphosphonate; OP, osteoporosis; BRONJ, BP-related osteonecrosis of the jaws; ONJ,
osteonecrosis of the jaws; MBL, marginal bone loss; DI, dental implant; SR, survival rate; ND, no data available.
Table 12. Studies that indicate dental implant outcomes in patients who underwent bisphosphonate treatment.
Author, year,
study design
Follow-
up
No. of patients No. of
implants
SR of
implant
Peri-
implant
pathology
Conclusion
Kovacs, 2001,
Retrospective [65]
10
years (3
years of
mean)
30 (received
postsurgical adjuvant
CT) and 17 (received
only oncological
surgery)
106 in CT
group,
54 in
surgery
group
98.1% on
implant
basis
– CT is not detrimental to the
survival and success of DIs
in the mandible
Cao and
Weischer, 2003
[66] (abstract
available)
? 27 total number of
nonirradiated and
irradiated patients
131 total 65% on
patient basis
– Implants and prostheses in
irradiated patients have
significantly lower survival
rates than in nonirradiated
patients
Korfage et al.,
2011,
Prospective [67]
5 years 50 (18 patients were
treated with surgery
only, 32 patients with
RT in addition to the
surgery)
195 (72 in
surgery-,
and 123 in
surgery +
RT)
98.6% for
non-RT
treated,
89.4% for
RT-treated
group
– Implant loss is higher in
patients with head and
neck cancer who received
RT posttumor surgery
Gander et al.,
2014,
Retrospective [26]
20
months
33 (29 patients with
SCC, 24 underwent
mandibular
reconstruction)
136 total 92.5% (at 1st
year), 87.5%
(after 20th
month)
– Only smoking (p = 0.016)
and alcohol abuse (p =
0.001) are associated with
higher implant failure rates
SCC, squamous cell carcinoma; CT, chemotherapy; RT, radiotherapy; DI, dental implant; SR, survival rate; ND, no data
available.
Table 13. Studies that indicate dental implant outcomes in head and neck oncology patients.
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Author, year,
study design
Follow-
up
No. of patients No. of implants SR of implant Peri-
implant
pathology
Conclusion
Moy et al., 2005,
Retrospective
cohort [6]
2–20
years
22 patients received RT ND 68.18% in irradiated
patients
– There is a correlation between head and
neck radiation and increased failure rate (RR
= 2.73)
Alsaadi et al.,
2008,
Retrospective [21]
2 years 2 patients received RT 15 in irradiated patients 80% – RT is affected significantly the late implant
loss (OR: 3.32)
Carr, 2012,
Retrospective
case series [69]
2 years ND (412 total) ND (1512 total) ND ND Late implant failure is influenced by the
local factor of “implant location” and the
systemic factor of “radiotherapy”
Mancha, 2012,
Retrospective [70]
5 years 30 RT-group, 20 control (non-RT
treated oral cancer group)
225 in RT group, 130 in
control group
92.6% for irradiated
(48.3% for ORN-
developed patients)
– Irradiated patients have significantly higher
implant loss than nonirradiated patients (p =
0.063)
Korfage et al.,
2014,
Retrospective [71]
14
years
164 patients with oral cancer
(also 91 of them are smoker, 65
are nonsmoker)
318 in RT-group, 206 in
nonirradiated group
91.5% for irradiated,
99.5% for
nonirradiated
– Implant loss is higher in irradiated patients
(p < 0.001) but no significant difference is
shown for bone loss assessed on panoramic
radiographs Smoking is also not found
associated with the occurrence of ORN
Rana et al., 2016,
Retrospective [72]
5 years 46 patients with oral cancer 162 67% (52 implant had
lost)
RT dose of <50 Gy units also showed
significantly increased amount of implant
survival rate
Nooh, 2013,
Systematic
Review [68]
1–14
years
944 patients with oral cancer 3775 88.9% (for 3357
implants)
– In preimplantation RT, SR of DI is
significantly higher for the mandible (93.3%)
than for the maxilla (78.9%) or for grafted
bone (87.5%) While RT dose above 55 Gy
significantly decreased implant survival
Mean/total of
values/subjects
1–20
years
284 patients with oral cancer (in
5 out of 6 available studies), 54
irradiated patients (in 3/6)
720 implants in
irradiated patients (in 4
out of 6 available
studies)
Approx. 83.07% SR
in irradiated patients
RT, especially a dose above 50 Gy, negatively
affects DI success
ORN, osteoradionecrosis; RT, radiotherapy; DI, dental implant; OR, odds ratio; RR, risk ratio; SR, survival rate; ND, no data available.
Table 14. Studies that indicate dental implant outcomes in patients who underwent radiation therapy.
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2.12.1. Radiotherapy and hyperbaric oxygen therapy
RT reduces the cellular and vascular processes of healing, therefore it is assumed to impair the
osseointegration and increase the risk of DI-related complications [31]. RTdoses higher than 50
Gy are known to hinder osseointegration of DIs [30]. On the other hand, DI placement
becomes contraindicated in patients who have received additional therapy of BFs intrave-
nously or hormonal therapy, corticosteroids or immunosuppressive medication [30].
According to the data retrieved from the recent studies, it can be concluded that implant loss
is clearly higher in irradiated patients (Table 14). The failures are more prominent in mandible
or in grafted bone [68].
In the past, adjuvant hyperbaric oxygen therapy (HBO) treatment was shown to lead lower DI
failure rates in cancer patients who underwent RT than those nonirradiated and irradiated
patients [73]. Whereas, according to the recent clinical studies and reviews (Table 15), it seems
that HBO has no positive effect on implant survival in irradiated patients. Therefore, this issue
remains controversial.
Author, year,
study design
Follow-
up
No. of
patients
No. of
implants
SR of implant Peri-implant
pathology
Conclusion
Schoen et al.,
2007, RCT [74]
1 year 26 (the half
is HBO
treated,
others is
control)
ND 85.2% in HBO
group, 93.9%
in non-HBO
group
MBLs: 0.6  0.6
mm in HBO-, 0.7
 0.7 mm in non-
HBO group
Adjuvant hyperbaric oxygen
therapy does not influence
implant survival or peri-
implant MBL in radiated
mandibular jaw bone. There is
no statistically significant
difference for postoperative
complications and patient
satisfaction
Esposito and
Worthington,
2013,
Systematic
review [75]
– – – – – Despite the limited amount of
clinical research available, it
appears that HBO therapy in
irradiated patients requiring
dental implants may not offer
any appreciable clinical
benefits. There is a definite
need for more RCTs to
ascertain the effectiveness of
HBO in irradiated patients
requiring dental implants
Chambrone
et al., 2013,
Systematic
review [76]
– – 1689 in
irradiated
jaws
The mean SR
of 15 studies
ranged from
46.3 to 98.0%
– The risk of implant failure
increases significantly in
irradiated patients (RR: 2.74)
and in maxillary sites (RR:
5.96). HBO therapy does not
reduce the risk of implant
failure
HBO, hyperbaric oxygen; RR, risk ratio; RCT, randomized controlled trial; MBL, marginal bone loss.
Table 15. The effect of hyperbaric oxygen (HBO) on reducing the risk of DI failure in irradiated patients.
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2.13. Immunosuppressive conditions
Immunosuppressive disabilities encompass several disorders and conditions including RDs,
autoimmune skin diseases (scleroderma, pemphigus, burning mouth syndrome etc.), organ
transplantation, and immunosuppressive drug usage [2, 77, 78].
Since a good immune response is necessary for wound healing, immunocompromised condi-
tions have been commonly assumed as a contraindication for DI placement [31]. In animal
studies, it is showed that immunosuppressive drugs reduce osteoblast’s proliferation and
impair implant osseointegration [79, 80]. Furthermore, immunocompromised condition may
present additional risks for blood borne infections [28]. Therefore, installation of DIs in
patients under long-term immunosuppressive treatment should be elucidated with additional
measures [81].
2.13.1. Organ transplantation
Bone healing is negatively affected by immunosuppressive medications. There are reports of
case series and clinical studies that show successful treatments of DIs in patients who
underwent organ transplants (Table 16). Reviewers stated that DIs could be a valid treatment
providing that the appropriate surgical procedures and hygienic conditions are ensured
[28, 78]. Modification of the immunosuppressive medication could lead a significantly lower
toxicity [78].
As a conclusion, it is apparent that DI is not contraindicated for the patients who had organ
transplants. However, it is suggested that the patients’ medical condition should be investi-
gated with the relevant physician before DI surgery, and the surgery should also be conducted
under prophylactic medication in order to reduce the risk of blood-borne infections [28, 31].
2.13.2. HIV-positive patients
Acquired immune deficiency syndrome (AIDS) is a condition that is caused by the infection of
the human immunodeficiency virus (HIV). HIV-infected individuals may have compromised
oral health because of having HIV-associated gingivitis and periodontitis etc. [85] that yield an
additional impairment of the general health.
Recently, HIV-infection is regarded as a chronic disease rather than a terminal disease owing to
the therapeutic regimen of highly active antiretroviral therapy (HAART) that includes combi-
nations of diverse antiretroviral medications. This regimen, however, is associated with many
adverse effects including bone disorders, osteopenia, osteonecrosis, and osteoporosis [86, 87].
Hence, there is a need for identifying the predictability of dental implant therapy in patients
with HIV-infection.
According to the clinical studies available (Table 17), clinical outcomes regarding the peri-
implant pathology are conflicting. There may be a tendency for peri-implant infections due to
the immunocompromised condition. However, HIV infection does not seem to increase the
failure in the short or long term. So DI could be regarded as an eligible treatment for improv-
ing quality of life in the HIV-positive patients.
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2.14. Psychiatric disorders
Patients with neurologic disorders or other disabilities such as cerebral palsy, mental retarda-
tion, epilepsy, Down syndrome, Rett’s syndrome, Asperger syndrome, Prader-Willi syndrome,
fragile X chromosome, dystrophia myotonica, autism, and schizophrenia cause many prob-
lems during implant treatment and prosthetic maintenance [93]. Epilepsy impairs the oral
condition of patients due to nausea-induced vomiting, mechanical trauma caused by seizures,
and antiepileptic drugs-associated oral complications such as gingival overgrowth, xerostomia,
and yeast infections [94, 95]. Likewise, most widely used antidepressant drugs, selective seroto-
nin reuptake inhibitors (SSRIs), affect not only the nervous system but also peripheral tissues
Author, year,
study design
Follow-
up
No. of patients No. of
implants
SR of
implant
Peri-implant
pathology
Conclusion
Gu and Yu,
2011, Case
series [82]
3 years 13 45 100% MBL is 1.30 mm DI treatment can be
offered to liver transplant
patients who are stable
under long-term
immunosuppression.
Stable liver function and
general condition should
be affirmed though overall
examination and
consultation
Gu et al., 2011,
Case report [83]
(only abstract
available)
5 years 1 11 – – A stable osseointegration
with moderate vertical
bone loss is achieved
Montebugnoli
et al., 2012,
Prospective [84]
3
months
20 (10 have
organ
transplant, the
other 10 are in
control group)
32 (20 in
transplanted,
12 in control
group)
– MBL is 0.21 mm for
transplanted, 0.32
mm is for control
group
The bone response around
submerged DI in
immunocompromised
organ transplant patients
does not differ from that
observed in control
patients
Montebugnoli
et al., 2015,
Prospective [81]
1 year 13 organ
transplanted
(11 hearts, two
livers, and 13
control
subjects)
29 in
transplanted,
28 in healthy
control
subjects
– For transplanted and
control subjects,
MBLs are 0.17 and
0.20 mm, PDs are
0.06 and 0.11 mm
It seems that bone and
periodontal response and
microbiological status
around submerged DI in
immunocompromised
organ-transplanted
patients do not differ 1
year after loading from
those observed in healthy
control patients
Mean/total of
values/subjects
1–5
years
37 patients had
organ-
transplant
105 implants 100% 0.19 mm for 1st year
1.30 mm at 3rd year
SR outcome is scarce. MBL
seems acceptable More
studies needed
MBL, marginal bone loss; DI, dental implant; SR, survival rate; PD, pocket depth.
Table 16. Studies that indicate dental implant outcomes in patients who received organ transplant.
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Author, year, study
design
Follow-up No. of patients No. of
implants
SR of implant Peri-implant pathology Conclusion
Stevenson et al.,
2007,
Prospective [88]
6 months 20 HIV+, and 9 HIV
edentulous adults
40 in HIV+, 18
in HIV
subjects
100% for both
groups
– No difference in short-term clinical outcome is
found between the HIV+ and the HIV subjects
Oliveira et al., 2011,
Pilot study [89]
1 year 40 (11 PI-based
HAART, 14 NNRTI-
based HAART
without PI, 15
control group of who
had HIV)
60 (20 in each
groups)
100% for all
groups
0.49 mm in PI-HAART
group, 0.47 mm in
NNRTI-HAART and 0.55
mm in control
The placement of DI in HIV+ patients is a
reasonable treatment, regardless of CD4+ cell
count, viral load levels, and type of antiretroviral
therapy. Longer follow-ups are necessary to
ascertain the success
Neves et al., 2016,
Retrospective [2]
7.3 years
of mean
5 HIV+ ND 60% (patient
based)
60% (patient-based peri-
implant pathology rate)
AIDS is not risk factor for neither higher implant
failure nor peri-implant pathology (>4 mm pocket
depth with BoP or MBL). However, these rates are
high when compared mean failure rates of
population
Gherlone et al.,
2016, Prospective
[90, 91]
1 year 66 HIV+ 190 92.1% on
implant basis
(a, b)
MBL is 1.19 mm, peri-
implantitis prevalence is
5.2% on implant basis (a,
b)
Despite higher incidence of peri-implant infections
in the first 6 months (a), DI is a suitable treatment
with a slightly worse results (a, b) regardless of
CD4+ cell count (b). HIV+ heavy smokers (>10 cig/
day) demonstrated increased risk of early failure,
peri-implantitis, pus, and pain (b)
Gay-Escoda et al.,
2016, Retrospective
case series [92]
6.5 years
of mean
9 HIV+ 57 98.3% Success rate: 68.4%.
Patient- and implant-
based rates of peri-
implant mucositis:
22.2%–10.5%, peri-
implantitis: 44.4%–45.6%
Though there is a high prevalence of peri-implant
diseases, DI in HIV+ patients seem to provide
satisfactory clinical results
Mean/total of
values/subjects
Up to 7.3
years
125 HIV+ patients 347 (in 4 out of
5 studies)
Approx. 90%
SR
0.83 mmMBL in 1st year.
50% of peri-implant
pathology rate for mean
follow-up of 7 years
SR is acceptable. Mean MBL outcomes are scarce
and conflicting. Peri-implant pathology incidences
seem higher as compared to the healthy
population
HAART, highly active anti-retroviral therapy; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; MBL, marginal bone loss; BoP, bleeding on
probing; SR, survival rate; resp, respectively.
Table 17. Studies that indicate dental implant outcomes in HIV-infected patients.
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including bones because of having serotonin receptors [96]. Therefore, SSRI blocks on bone cells
have been reported to affect bone formation negatively [97].
Since bone metabolism and oral conditions have an influence on the osseointegration of DI,
neuropsychiatric disabilities and the drugs used are considerable issues for DI treatment.
Clinical research related to the effect of psychiatric disorders on DI success is limited. It seems
that this kind of disorders do not cause higher failures or peri-implant pathology (Table 18).
On the other hand, SSRIs might increase DI failure rate as presented in a cohort study with a
large number of subjects. Further studies are required to ascertain the association between
antidepressant drugs and DI failure.
3. Conclusion
Implant survival in the elderly population, osteoporosis (OP) and HIV infection seem to be
similar with the healthy population. CVDs or diabetes may present a small risk. RT seems to
have the worst effect on DI success with an average SR of 83%. Some of the other compromised
conditions such as alcoholism, bleeding disorders, thyroid disorders, hepatitis, RDs, organ
transplantation, and HBO therapy should be investigated with additional clinical data to
reveal objective conclusions regarding DIs.
Author, year,
study design
Follow-
up
No. of patients No. of
implants
SR of
implant
Peri-implant pathology Conclusion
Cune et al., 2009,
Retrospective [95]
16
years
61 patients
with epilepsy,
additional
motor and/or
intellectual
impairments
134 97.6% 72% of implants were
considered having
inadequate level of
hygiene PD is 2 mm
Although adequate
plaque control is not
feasible in those
patients, MBLs
remained stable and
implant loss is rare
Ekfeldt et al.,
2013,
Prospective [93]
10
years
22 patients
with different
neurologic
disabilities
70 85.8% Peri-mucositis: 14
implants in 10 patients
(PD ≥ 4 mm). Peri-
implantitis: 4 implants
in 3 patients (bone loss ≥
3 threads)
DI is a valid option in
patients with ND,
although maintenance
often requires the
management of more
complications
compared with healthy
patients
Wu et al., 2014,
Retrospective
cohort [98]
3–67
months
490 total
number of
SSRI-users and
nonusers
916 (94 in
users, 822
in
nonusers)
88.4%
for
users,
95.4%
for
nonusers
– SSRI is associated with
increased failure risk of
osseointegrated
implants, which might
suggest a careful
surgical treatment
planning for SSRI users
ND, neurologic disabilities; SSRI, selective serotonin reuptake inhibitor; PD, probing depth; MBL, marginal bone loss; SR,
survival rate.
Table 18. Studies that indicate dental implant outcomes in patients with psychiatric disorders.
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Results with regard to peri-implantitis or peri-implant conditions are insufficient and even
conflicting for majority of the compromising systemic aspects. Future studies should be
designed for indicating peri-implant tissue health and maintenance in compromised patients.
It must be taken into account that follow-up of the patients in a professional oral maintenance
regimen after implant placement reduces the implant failure rate by 80% [12]. Thus, it can be
stated that controlling the systemic diseases before the implant therapy and proper establish-
ment of the medical conditions are more important than the presence of a compromise alone.
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